Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
Journals
Diseases
Special Issues
Pathogenesis of Pancreatic Cancer
share announcement

Pathogenesis of Pancreatic Cancer

A special issue of Diseases (ISSN 2079-9721). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (30 November 2018) | Viewed by 9120

Special Issue Editor

Prof. Dr. Marco Falasca

E-Mail Website
Guest Editor
Department of Medicine and Surgery, University of Parma, Via Volturno, 39, 43125 Parma, Italy
Interests: lipid metabolism; gastrointestinal diseases; pancreatic cancer; extracellular vesicles; tumour-stroma crosstalk; cannabinoid signalling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pancreatic ductal adenocarcinoma (PDAC) is still one of the most aggressive and lethal malignancy in Western countries, with a low survival rate of around 5% that has remained unchanged for the last 40 years. The reason for this standstill resides in both the difficulty in diagnosing the disease at an early stage, due to non-specificity or lack of symptoms, and the inefficacy of the treatments currently available, caused by resistance to chemotherapy and radiotherapy. PDAC cells are characterised by a tendency to infiltrate into the endothelium basement membrane and neurons and to propagate speedily to distant organs through the lymphatic system, causing metastasis. At molecular level, it is known that the activation of oncogenes, such as KRAS and NOTCH, and the blocking of tumour suppressor genes like p16, p53, SMAD4 and PTEN, are involved in the initiation and advancement of this disease. In addition, various cell signalling pathways, such EGFR, Akt and NF-kB, have been found to be disrupted, contributing to PDAC evolution. Despite all these advances in the understanding of the molecular pathogenesis of PDAC, further insight in the knowledge of this disease and new efficacious therapeutic strategies are urgently required in order to improve the outcomes for PDAC patients.

Prof. Dr. Marco Falasca
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic cancer
  • pancreatic ductal adenocarcinoma
  • molecular pathogenesis
  • chemotherapy
  • metastasis
  • cancer biology

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 938 KiB  
Review
The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
by Ashleigh Parkin, Jennifer Man, Angela Chou, Adnan M Nagrial, Jaswinder Samra, Anthony J Gill, Paul Timpson and Marina Pajic
Diseases 2018, 6(4), 103; https://doi.org/10.3390/diseases6040103 - 13 Nov 2018
Cited by 6 | Viewed by 4284
Abstract
Pancreatic cancer is the third leading cause of cancer-related deaths, characterised by poor survival, marked molecular heterogeneity and high intrinsic and acquired chemoresistance. Only 10–20% of pancreatic cancer patients present with surgically resectable disease and even then, 80% die within 5 years. Our [...] Read more.
Pancreatic cancer is the third leading cause of cancer-related deaths, characterised by poor survival, marked molecular heterogeneity and high intrinsic and acquired chemoresistance. Only 10–20% of pancreatic cancer patients present with surgically resectable disease and even then, 80% die within 5 years. Our increasing understanding of the genomic heterogeneity of cancer suggests that the failure of definitive clinical trials to demonstrate efficacy in the majority of cases is likely due to the low proportion of responsive molecular subtypes. As a consequence, novel treatment strategies to approach this disease are urgently needed. Significant developments in the field of precision oncology have led to increasing molecular stratification of cancers into subtypes, where individual cancers are selected for optimal therapy depending on their molecular or genomic fingerprint. This review provides an overview of the current status of clinically used and emerging treatment strategies, and discusses the advances in and the potential for the implementation of precision medicine in this highly lethal malignancy, for which there are currently no curative systemic therapies. Full article
(This article belongs to the Special Issue Pathogenesis of Pancreatic Cancer)
►▼ Show Figures

Figure 1

12 pages, 251 KiB  
Review
Pancreatic Cystic Lesions: Pathogenesis and Malignant Potential
by Antoinette J. Pusateri and Somashekar G. Krishna
Diseases 2018, 6(2), 50; https://doi.org/10.3390/diseases6020050 - 13 Jun 2018
Cited by 12 | Viewed by 4257
Abstract
Pancreatic cancer remains one of the most lethal cancers despite extensive research. Further understanding of precursor lesions may enhance the ability to treat and prevent pancreatic cancer. Pancreatic cystic lesions (PCLs) with malignant potential include: mucinous PCLs (intraductal papillary mucinous neoplasms and mucinous [...] Read more.
Pancreatic cancer remains one of the most lethal cancers despite extensive research. Further understanding of precursor lesions may enhance the ability to treat and prevent pancreatic cancer. Pancreatic cystic lesions (PCLs) with malignant potential include: mucinous PCLs (intraductal papillary mucinous neoplasms and mucinous cystic neoplasm), solid pseudopapillary tumors and cystic neuroendocrine tumors. This review summarizes the latest literature describing what is known about the pathogenesis and malignant potential of these PCLs, including unique epidemiological, radiological, histological, genetic and molecular characteristics. Full article
(This article belongs to the Special Issue Pathogenesis of Pancreatic Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop